Coullet Julien, Guëll José-Luis, Fournié Pierre, Grandjean Hélène, Gaytan Javier, Arné Jean-Louis, Malecaze François
Ophthalmology Department, Purpan Hospital, Toulouse, France.
Am J Ophthalmol. 2006 Dec;142(6):909-16. doi: 10.1016/j.ajo.2006.07.021. Epub 2006 Aug 31.
To compare refractive performance of Artisan (Ophtec, Groningen, The Netherlands) or Verisyse phakic intraocular lens and its foldable version, Artiflex (Ophtec), for the correction of moderately high myopia.
Randomized pilot study.
setting: Institutional practice. patient population: Thirty-one patients with myopia that ranged from -6 to -14 diopters (D). interventional procedure: One eye was implanted with an Artisan phakic intraocular lens (PIOL) and the other with an Artiflex PIOLs. main outcome measures: Primary outcome measure was the percentage of eyes with uncorrected visual acuity (UCVA) of >20/40 at one year after the operation. Main secondary outcome measures were the safety index, the change of two lines or more of best spectacle-corrected visual acuity (BSCVA) and the endothelial cell count.
No intraoperative complications were noticed. One year after surgery, the percentage of eyes with UCVA of >20/40 was 51.6% (16/31 patients) for Artisan-treated eyes and 77.4% (24/31 patients) for Artiflex-treated eyes (P = .033). One month after surgery, this same percentage was 42.9% (13/31 patients) and 77.4% (24/31 patients), respectively (P = .004). The safety index at one year was 1.13 +/- 0.24 for Artisan-treated eyes and 1.12 +/- 0.21 for Artiflex-treated eyes, which is a difference that was not statistically significant (P = 0.742). At one year after surgery, the changes of two lines or more of BSCVA and the endothelial cell loss were similar for both groups.
To correct moderately high myopia, the Artiflex lens provides a faster visual recovery and a better UCVA than does the Artisan lens. The safety of the lens should be supported by an enlarged sample size and a longer follow-up period.
比较Artisan(荷兰格罗宁根Ophtec公司)或Verisyse有晶状体眼人工晶状体及其可折叠版本Artiflex(Ophtec)矫正中度高度近视的屈光性能。
随机试点研究。
设置:机构实践。患者人群:31例近视度数在-6至-14屈光度(D)之间的患者。干预程序:一只眼植入Artisan有晶状体眼人工晶状体(PIOL),另一只眼植入Artiflex PIOL。主要观察指标:主要观察指标是术后一年未矫正视力(UCVA)>20/40的眼的百分比。主要次要观察指标是安全指数、最佳矫正视力(BSCVA)提高两行或更多行的变化以及内皮细胞计数。
未观察到术中并发症。术后一年,Artisan治疗组眼的UCVA>20/40的百分比为51.6%(16/31例患者),Artiflex治疗组眼为77.4%(24/31例患者)(P = 0.033)。术后一个月,该百分比分别为42.9%(13/31例患者)和77.4%(24/31例患者)(P = 0.004)。Artisan治疗组眼一年时的安全指数为1.13±0.24,Artiflex治疗组眼为1.12±0.21,差异无统计学意义(P = 0.742)。术后一年,两组BSCVA提高两行或更多行的变化以及内皮细胞损失相似。
矫正中度高度近视时,Artiflex晶状体比Artisan晶状体视觉恢复更快,UCVA更好。晶状体的安全性应通过扩大样本量和延长随访期来证实。